News
TRIB
1.820
-0.55%
-0.010
Weekly Report: what happened at TRIB last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at TRIB last week (0408-0412)?
Weekly Report · 04/15 09:27
Weekly Report: what happened at TRIB last week (0401-0405)?
Weekly Report · 04/08 09:29
Trinity Biotech Accelerates Transformation and Growth
TipRanks · 04/05 17:27
TRIB Stock Earnings: Trinity Biotech Misses EPS, Misses Revenue for Q4 2023
Trinity Biotech reported earnings per share of -72 cents for the fourth quarter of 2023. The company reported revenue of $13.43 million. This was 10.48% worse than the analyst estimate for revenue. Trinity Biotech is a biotechnology company.
Investorplace · 04/04 15:52
Trinity Biotech Says It Is Targeting Approximately $20M Of Annualized Run-rate EBITDA On Annualized Run-rate Revenues Of Approximately $75M By Q2, 2025
Benzinga · 04/04 11:45
Trinity Biotech Q4 EPS $(0.72) Up From $(1.33) YoY, Sales $13.43M Miss $15.00M Estimate
Trinity Biotech reported quarterly losses of $0.72 per share. The company reported quarterly sales of $13.43 million which missed the analyst consensus estimate of $15.00 million. Trinity Biotech also reported a 45.86 percent increase in sales from the same period last year.
Benzinga · 04/04 11:42
Trinity Biotech reports Q4 results
Seeking Alpha · 04/04 11:33
TRINITY BIOTECH - ANNOUNCING AN INITIATIVE TO MOVE SIGNIFICANT ASPECTS OF OUR BUSINESS SUPPORT FUNCTIONS TO A LOWER COST AND CENTRALISED LOCATION
Reuters · 04/04 11:30
TRINITY BIOTECH PLC- TARGETING ABOUT $20 MLN OF ANNUALISED RUN-RATE EBITDASO1 ON ANNUALISED RUN-RATE REVENUES OF APPROXIMATELY $75 MLN BY Q2, 2025
Reuters · 04/04 11:30
TRINITY BIOTECH- SIGNIFICANTLY REDUCING COST OF GOODS OF MANY OF OUR PRODUCTS BY CHANGING SUPPLIERS AND NEGOTIATING NEW DEALS WITH EXISTING SUPPLIERS
Reuters · 04/04 11:30
Earnings Scheduled For April 4, 2024
Conagra Brands is likely to report quarterly earnings at $0.65 per share on revenue of $3.01 billion. Trinity Biotech is projected to report earnings for its fourth quarter. Other companies reporting before and after the bell include AngioDynamics and Simply Good Foods.
Benzinga · 04/04 09:18
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics. The company announced results for the quarter ended December 31, 2023 and fiscal year 2023. Trinity Biotech is headquartered in Dublin, Ireland.
Barchart · 04/04 06:30
Notable earnings before Thursday's open
Major earnings expected before the bell on Thursday include: Conagra Brands, Lindsay, and Lamb Weston Holdings. Other major earnings slated for release before Thursday's open include: ANGO, RPM, RDUS, SMPL, TRIB. Notable earnings before the open include Conagra and Lindsay.
Seeking Alpha · 04/03 14:17
Weekly Report: what happened at TRIB last week (0325-0329)?
Weekly Report · 04/01 09:28
Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
Trinity Biotech plc will report financial results for the fourth quarter and fiscal year 2023 on April 4, 2024 at 8:00am ET. Trinity Biotech is a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets.
Barchart · 03/28 17:39
Weekly Report: what happened at TRIB last week (0318-0322)?
Weekly Report · 03/25 09:29
Weekly Report: what happened at TRIB last week (0311-0315)?
Weekly Report · 03/18 09:29
Weekly Report: what happened at TRIB last week (0304-0308)?
Weekly Report · 03/11 09:28
Weekly Report: what happened at TRIB last week (0226-0301)?
Weekly Report · 03/04 09:29
More
Webull provides a variety of real-time TRIB stock news. You can receive the latest news about Trinity Biotech Plc through multiple platforms. This information may help you make smarter investment decisions.
About TRIB
Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic systems, including both reagents and instrumentation for the clinical laboratory and point-of-care segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ. The Company manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.